Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans

Vaccine

Volumn 27, Issue 39, 2009, Pages 5344-5348

  Couch, Robert B ^a   Atmar, Robert L ^a   Cate, Thomas R ^a   Quarles, John M ^b   Keitel, Wendy A ^a   Arden, Nancy H ^b   Wells, Janet ^a   Niño, Diane ^a   Wyde, Philip R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

Adjuvants; Inactivated influenza vaccine; Interferon; Mice and humans; Mucosal antibody

Indexed keywords

CHOLERA TOXIN B SUBUNIT; IMMUNOGLOBULIN A ANTIBODY; INFLUENZA VACCINE; INTERFERON; NEUTRALIZING ANTIBODY; PHOSPHORYL LIPID A; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; HUMAN; HUMAN EXPERIMENT; LUNG FLUID; MOUSE; MUCOSA; NONHUMAN; NORMAL HUMAN; NOSE SECRETION; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, VIRAL; CHOLERA TOXIN; HUMANS; IMMUNITY, MUCOSAL; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERFERON TYPE I; LIPID A; MICE; MICE, INBRED ICR; NEUTRALIZATION TESTS; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 68449089230     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.084     Document Type: Article

References (43)

1. Couch R.B. Seasonal inactivated influenza virus vaccines. Vaccine 26S (2008) D5-D9
2. Couch R.B. An overview of serum antibody responses to influenza virus antigens. In: Brown F., Haaheim L.R., Wood J.M., and Schild G.C. (Eds). Developments in Biologicals: Laboratory Correlates of Immunity to Influenza 115 (2003), Karger, New York 25-30
3. Couch R.B., Kasel J.A., Six H.R., Cate T.R., and Zahradnik J.M. Immunological reactions and resistance to infection with influenza virus. In: Stuart-Harris C., and Potter C. (Eds). Molecular Virology and Epidemiology of Influenza, Beecham Symposium (1983), Academic Press, London 119-153
4. Keitel W.A., Couch R.B., Cate T.R., Hess K.R., Baxter B., Quarles J.M., et al. High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal antibody responses in healthy adults. J Clin Microbiol 32 10 (1994) 2468-2473
5. Treanor J.J. Influenza virus. In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Principles and Practice of Infectious Diseases. sixth ed. (2005), Elsevier Churchill Livingstone, Philadelphia 2060-2085
6. Ogra P.L., Karzon D.T., Righthand F., and MacGillivray M. Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection. New Engl J Med 279 (1968) 893
7. Ogra P.L., and Karzon D.T. Poliovirus antibody response in serum and nasal secretions following intranasal inoculation with inactivated poliovaccine. J Immunol 102 (1969) 15
8. Kasel J.A., Rossen R.D., Fulk R.V., Fedson D.S., Couch R.B., and Brown P. Human influenza: aspects of the immune response to vaccination. Ann Intern Med 71 (1969) 369-398
9. Atmar R.L., Keitel W.A., Cate T.R., Munoz F.M., Ruben F., and Couch R.B. A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine 25 (2007) 5367-5373
10. Tamura S., Asanuma H., Tomita T., Komase K., Kawahara K., Danbara H., et al. Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine. Vaccine 12 (1994) 1083-1089
11. Levi R., Aboud-Pirak E., Leclerc C., Lowell G.H., and Arnon R. Intranasal immunization of mice against influenza with synthetic peptides anchored to Proteosomes. Vaccine 13 (1995) 1353-1359
12. Tamura S.-I., Funato H., Hirabayashi Y., Kikuta K., Suzuki Y., and Nagamine T. Functional role of respiratory tract haemagglutiinin-specific IgA antibodies in protection against influenza. Vaccine 8 5 (1990) 479-485
13. Baldridge J.R., Yorgensen Y., Ward J.R., and Ulrich J.T. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 18 (2000) 2416-2425
14. McCluskie M.J., and Davis H.L. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine 19 (2000) 413-422
15. Glu{combining double acute accent}ck U., Gebbers J.-O., and Glu{combining double acute accent}ck R. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J Virol 73 (1999) 7780-7786
16. ®/chitosan) enhances the immune response to intranasally administered tetanus toxoid. Vaccine 20 (2002) 711-723
17. Proietti E., Bracci L., Puzelli S., Di Pucchio T., Sestili P., De Vincenzi E., et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol 169 (2002) 375-383
18. Halperin S.A., Smith B., Clarke K., Treanor J., Mabrouk T., and Germain M. Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults. Human Vaccin 1 (2005) 37-42
19. Treanor J., Nolan C., O'Brien D., Burt D., Lowell G., Linden J., et al. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induced serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 24 (2006) 254-262
20. Mizuno D., Ide-Kurihara M., Ichinomiya T., Kubo I., and Kido H. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen. J Immunol 176 (2006) 1122-1130
21. Samo T.C., Greenberg S.B., Couch R.B., Quarles J., Johnson P.E., Hook S., et al. Efficacy and tolerance of intranasally applied recombinant leukocyte A interferon in normal volunteers. J Infect Dis 148 3 (1983) 535-542
22. Samo T.C., Greenberg S.B., Palmer J.M., Couch R.B., Harmon M.W., and Johnson P.E. Intranasally applied recombinant leukocyte A interferon in normal volunteers. II. Determination of minimal effective and tolerable dose. J Infect Dis 150 2 (1984) 181-188
23. Greenberg S.B., and Couch R.B. Interferon for respiratory virus infections in man. The Interferon System, A Current Review (1986), University of Texas Press, Galveston, TX
24. Robinson R.Q., and Dowdle W.R. Influenza viruses. In: Lennette E.H.S.N.J. (Ed). Diagnostic Procedures for Viral and Rickettsial Infections (1969), American Public Health Association, Inc., New York 414-433
25. Chen D., Periwal S.B., Larrivee K., Zuleger C., Erickson C.A., Endres R.L., et al. Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization. J Virol 75 (2002) 7956-7965
26. Frank A.L., Puck J., Hughes B.J., and Cate T.R. Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement. J Clin Microbiol 12 (1980) 426-432
27. Greenbaum E., Furst A., Kiderman A., Stewart B., Levy R., Schlesinger M., et al. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine. J Med Virol 65 (2001) 178-184
28. Greenbaum E., Furst A., Kiderman A., Stewart B., Levy R., Schlesinger M., et al. Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine. Vaccine 20 (2002) 1232-1239
29. Greenbaum E., Engelhard D., Levy R., Schlezinger M., Morag A., and Zakay-Rones Z. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine. Vaccine 22 (2004) 2566-2577
30. Cox E., Verdonck F., Vanrompay D., and Goddeeris B. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. Vet Res 37 (2006) 511-539
31. Wyde P.R., Guzman E., Gilbert B.E., and Couch R.B. Immunogenicity and protection in mice given inactivated influenza vaccine, MPL, QS-21 or QS-7. In: Osterhaus A.D.M.E., Cox N., and Hampson A.W. (Eds). Options for the Control of Influenza IV (2001), Excerpta Medica, New York 999-1005
32. Mbawuike I.M., Zang Y., and Couch R.B. Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant. Vaccine 25 (2007) 3263-3269
33. Hashigucci K., Ogawa H., Ishidate T., Yamashita R., Kamiya H., Watanabe K., et al. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine 14 (1996) 113-119
34. Stephenson I., Zambon M.C., Rudin A., Colegate A., Podda A., Bugarini R., et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 80 (2006) 4962-4970
35. Havell E.A., and Vilček J. Production of high-titered interferon in cultures of human diploid cells. Antimicrob Agents Chemother 2 (1972) 476-484
36. Muszkat M., Greenbaum E., Ben-Yehuda A., Oster M., Yeu E., Heimann S., et al. Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine. Vaccine 21 (2003) 1180-1186
37. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 13 (2006) 1343-1351
38. Leroux-Roels I., Borkowski A., Vanwolleghem T., Dramé M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370 (2007) 580-589
39. Liew F.Y., Russell S.M., Appleyard G., Brand C.M., and Beale J. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity. Eur J Immunol 14 (1984) 350-356
40. Waldman R.H., Wigley F.M., and Small Jr. P.A. Specificity of respiratory secretion antibody against influenza virus. J Immunol 108 (1970) 1477-1483
41. Baccala R., Kono D.H., and Theofilopoulos A.N. Interferons as pathogenic effectors in autoimmunity. Immunol Rev 204 (2005) 9-26
42. Boyce T.G., Hsu H.H., Sannella E.C., Coleman-Dockery S.D., Baylis E., Zhu Y., et al. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine 19 (2001) 217-226
43. Samdal H.H., Bakke H., Oftung F., Holst J., Haugen I.L., Korsvold G.E., et al. A non-living nasal influenza vaccine can induce major humoral and cellular immune responses in humans without the need for adjuvants. Human Vaccin 1 (2005) 85-90